Evaluation of the Effectiveness of Hepatitis B Vaccination in Children Aged 1 to 14 Years in Sulaimani City

Razhan Sabah  Hassan; Ali Hattem  Bayati

doi:10.56056/amj.2018.63

Authors

Razhan Sabah Hassan Postgraduate student, Microbiology/Pathology, Kurdistan Board of Medical Specialties/ Kurdistan region-Iraq.
Ali Hattem Bayati Assistant Professor, Community Health Department, Technical College of Health, Sulaimani Polytechnic University, Sulaimani City, Kurdistan Region-Iraq.

DOI:

https://doi.org/10.56056/amj.2018.63

Keywords:

Antibody to hepatitis B surface antigen, Hepatitis B virus, Vaccination, Sulaimani City

Abstract

Background and objectives:Hepatitis-B virus is one of the most serious and prevalent health problems. Vaccination against Hepatitis-B virus is the most effective way of preventing infection and transmission of the virus. The aim of this study was to assess the effectiveness of hepatitis-B virus vaccination among children in Sulaimani city

Methods: A cross-sectional study was performed on 384 children aged between 1 and 14 years who received the scheduled 3 doses of hepatitis B virus vaccine in infancy period. Blood samples were taken from all children, and the sera were tested for antibody to hepatitis B surface antigen, antibody to hepatitis B core antigen, and hepatitis B surface antigen using enzyme-linked immunosorbent assay

Results: Hepatitis B surface antigen and total antibody to hepatitis B core antigen were negative in all children involved in the study whereas antibody to hepatitis B surface antigen was positive (antibody to hepatitis B surface antigen ? 10 mIU/mL) in 256 (66.7%) and negative (antibody to hepatitis B surface antigen < 10 mIU/mL) in 128 (33.3%) children; (77.3%) of children in the age group 1-5 years were positive for antibody to hepatitis B surface antigen, while the percentage was less (66.7%) in the age group 6-10 years and least (57.9%) in the age group 11-14 years, these differences in the age groups were statistically significant, p value <0.02.

Conclusions: Universal Hepatitis B virus vaccination program provided protection to nearly two thirds of children in Sulaimani city, Kurdistan Region, Iraq, and seronegative antibody to hepatitis B surface antigen exists in different age groups of the vaccinated children.

Downloads

Download data is not yet available.

References

André F. Hepatitis B epidemiology in Asia, the middle East and Africa. Vaccine. 2000; 18: 20-22.

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142: 1264-73.

Franco E, Bagnato B, Marino MG, et al. Hepatitis B: Epidemiology and prevention in developing countries. World journal of hepatology. 2012; 4: 74-80.

Shepard C, Simard E, Finelli L, et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic reviews. 2006; 28: 112- 25.

Gerlich W. Medical virology of hepatitis B: how it began and where we are now. Virology journal. 2013; 10: 239-63.

World Health Organization. Documenting the Impact of Hepatitis B Immunization: Best Practices for Conducting a Serosurvey. Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva. 2011. WHO document WHO/IVB/11.08. Available from: www. who.int/immunization/documents/who_ivb_11.08/en. Accessed April 23, 2014

Abdullah A, Badal R, Hussein R, et al. Hepatitis B Knowledge Among Healthy Volunteers in Duhok City, Kurdistan Region, Iraq. International Journal of Infection. 2017; 4: 976-9.

Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. International journal of medical sciences. 2005; 2: 50-7.

Lin S, Xie B, Liu J, Zhao X, et al. Effect of revaccination using different schemes among adults with low or undetectable anti-HBs titers after hepatitis B virus vaccination. Clinical and Vaccine Immunology. 2010;17: 1548-51.

Michel L, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathologie Biologie. 2010; 58: 288-95.

Alavian M, Tabatabaei V, Ghadimi T, et al. Seroprevalence of hepatitis B virus infection and its risk factors in the west of Iran: a population-based study. International journal of preventive medicine. 2012; 3: 770-75.

Shaaban F, Hassanin A, Samy S, et al. Long-term immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. Eastern Mediterranean Health Journal. 2007; 13: 750-57.

Rezaei M, Nooripoor S, Ghorbani R, et al. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. Journal of preventive medicine and hygiene. 2014; 55:1-3.

Alexandre F, Martins B, Souza M, et al. Brazilian hepatitis B vaccine: a six-year follow-up in adolescents. Memórias do Instituto Oswaldo Cruz. 2012; 107: 1060-63.

Aghakhani A, Banifazl M, Izadi N, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World Journal of Pediatrics. 2011; 7: 358-60.

Amy B, Baker J, Kozinetz A, et al. Duration of protection after infant hepatitis B vaccination series. Pediatrics. 2014; 133: 1500-07.

Gilca V, De Serres G, Boulianne N, et al. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine. 2013; 3: 448-51.

Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Bmj. 2002; 325: 569-73.

Nakao K, Hamasaki K, Wakihama N, et al. Analysis of anti-HBs levels in healthcare workers over 10 years following booster vaccination for hepatitis B virus. Vaccine. 2003; 21: 3789-94.

But K, Lai L, Lim L, et al. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children. Vaccine. 2008; 26: 6587-91.

AlFaleh F, AlShehri S, AlAnsari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. Journal of Infection. 2008; 57: 404-9.

Alavian M, Gouya M, Hajarizadeh B, et al. Mass vaccination campaign against hepatitis B in adolescents in Iran: estimating coverage using administrative data. Hepatitis Monthly. 2009; 9: 189-95.

Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25: 3511-14.

Alavian M, Fallahian F, Lankarani B. Implementing strategies for hepatitis B vaccination. Saudi Journal of Kidney Diseases and Transplantation. 2010; 21: 10-22.